Assay News and Research

RSS

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

26 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

SQI Diagnostics continues discussions with the FDA to market it's SQiDworks Diagnostics Platform in the US

SQI Diagnostics Inc. (TSX-V: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced its financial and operational results for the third quarter ended June 30, 2009.

24 Aug 2009

New noninvasive technique to detect colorectal and gastric cancers found

A preliminary evaluation of methylation of two gene promoters in fecal DNA showed promise as a noninvasive method to detect colorectal and gastric cancers, according to a new study published online August 21 in the Journal of the National Cancer Institute.

24 Aug 2009

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

GenWay Clinical Laboratory, a US-based diagnostic company with CLIA certification, has validated a general tumor marker test in their laboratory and now offers this testing service. This is an ELISA-based assay which simply requires a small blood sample from the patient in order to quantify the amount of the tumor marker in their serum.

24 Aug 2009

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

Southern Research Institute today announced that it has been selected as one of 11 organizations to help establish the National Cancer Institute's (NCI) Chemical Biology Consortium (CBC)--a program meant to coordinate and accelerate the discovery and development of new therapeutic agents to treat cancer patients. Southern Research will establish one of NCI's five Comprehensive Chemical Biology Centers at its Birmingham campus.

21 Aug 2009

Chemical components of elderberry, cinnamon and green tea extracts block HIV viruses from infecting cells

The development of new antiviral drugs has had a tremendous impact on the quality of life and life expectancy of HIV-positive and AIDS patients, as the drugs effectively disrupt the replication cycle of the HIV virus. Yet the regular use of those drugs - such as zidovudine (also known as azidothymidine or AZT), protease inhibitors, and highly active antiretroviral therapy (HAART) involving multidrug therapies - has led to resistant HIV strains.

20 Aug 2009

DNA evidence found at crime scenes can easily be falsified

Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced that company researchers have proven DNA evidence found at crime scenes can easily be falsified using basic equipment, know-how and access to DNA or a DNA database.

18 Aug 2009

FDA approves Helixate FS for routine prophylaxis in children with hemophilia A

CSL Behring announced today that Helixate® FS, Antihemophilic Factor (Recombinant), has been approved by the U.S. Food and Drug Administration (FDA) for routine prophylaxis in children with hemophilia A who are 16 years old or younger and do not have pre-existing joint damage.

17 Aug 2009

Transgenomic reports Q2 2009 financials

The Company reported a net loss of $730,000 or $0.01 per share for the second quarter of 2009 as compared to net income of $101,000 or $0.00 per share for the second quarter of 2008.

12 Aug 2009

New class of molecules capable of blocking formation of tau protein fibrils

A new class of molecules capable of blocking the formation of specific protein clumps that are believed to contribute to Alzheimer’s disease pathology has been discovered by researchers at the University of Pennsylvania School of Medicine. By assaying close to 300,000 compounds, they have identified drug-like inhibitors of AD tau protein clumping, as reported in the journal Biochemistry.

11 Aug 2009

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates.

10 Aug 2009

Research details role of galectin-3 in heart failure

BG Medicine today announced the publication of a peer-reviewed article on the role of galectin-3 in heart failure development and progression.

6 Aug 2009

Immune responses to flu vaccine are diminished in lupus patients

Patients with the autoimmune disease systemic lupus erythematosus (SLE) have an increased risk of infection, due to both disturbances in their immune responses and treatment with immunosuppressive drugs.

30 Jul 2009

New discovery on DNA repair mechanism

Researchers at Washington University School of Medicine in St. Louis have shed new light on a process that fixes breaks in the genetic material of the body's cells. Their findings could lead to ways of enhancing chemotherapy drugs that destroy cancer cells by damaging their DNA.

17 Jul 2009

Novel drug discovery tool could bring new therapies for Parkinson’s

Researchers funded by the National Institutes of Health have turned simple baker?s yeast into a virtual army of medicinal chemists capable of rapidly searching for drugs to treat Parkinson's disease.

13 Jul 2009

Nanofluidic biopsy detects subtle changes in cancer cells

By taking two standard laboratory techniques - capillary electrophoresis and antibody-based protein detection - and shrinking them to the nanoscale, researchers at the Stanford University School of Medicine have created a new method for detecting miniscule changes in the levels of proteins associated with cancer.

28 Jun 2009

Assay News and Research

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

SQI Diagnostics continues discussions with the FDA to market it's SQiDworks Diagnostics Platform in the US

New noninvasive technique to detect colorectal and gastric cancers found

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

Chemical components of elderberry, cinnamon and green tea extracts block HIV viruses from infecting cells

DNA evidence found at crime scenes can easily be falsified

FDA approves Helixate FS for routine prophylaxis in children with hemophilia A

Transgenomic reports Q2 2009 financials

New class of molecules capable of blocking formation of tau protein fibrils

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

Research details role of galectin-3 in heart failure

Immune responses to flu vaccine are diminished in lupus patients

New discovery on DNA repair mechanism

Novel drug discovery tool could bring new therapies for Parkinson’s

Nanofluidic biopsy detects subtle changes in cancer cells

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News